Search

Your search keyword '"Martino, Massimo"' showing total 23 results
Start Over Author "Martino, Massimo" Journal expert opinion on biological therapy
23 results on '"Martino, Massimo"'

2. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

4. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

16. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program

Author

Martino, Massimo, primary, Montanari, Mauro, additional, Bruno, Benedetto, additional, Console, Giuseppe, additional, Irrera, Giuseppe, additional, Messina, Giuseppe, additional, Offidani, Massimo, additional, Scortechini, Ilaria, additional, Moscato, Tiziana, additional, Fedele, Roberta, additional, Milone, Giuseppe, additional, Castagna, Luca, additional, and Olivieri, Attilio, additional

Published
2012
Full Text
View/download PDF

19. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Author

Martino, Massimo, Lanza, Francesco, Demirer, Taner, Moscato, Tiziana, Secondino, Simona, and Pedrazzoli, Paolo

Abstract

Introduction:Erythropoiesis-stimulating agents (ESAs) are used in treating cancer- and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.Areas covered:A systematic review has been conducted to examine the current evidence for the efficacy and safety of using ESAs in hematopoietic stem cell transplants (HSCTs).Expert opinion:Despite the international recommendations for the use of ESAs in treating different malignancies, there is a lack of guidelines for their use in patients undergoing HSCT. An evaluation of published clinical trials shows that there are no available powerful studies concerning the use of ESAs in this setting, with only heterogeneous and small numbers of patients reported so far. Nevertheless, the more robust and intriguing of these data suggest that the ESA’s administration at an appropriate time after the infusion of stem cells may be effective both in autologous and allogeneic HSCTs. New guidelines are required, overseen by an expert in the in the field of stem cell transplantation.

Published
2015
Full Text
View/download PDF

20. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well

Author

Martino, Massimo and Morabito, Fortunato

Abstract

In multiple myeloma (MM), the use of high-dose chemotherapy with autologous stem cell transplantation (ASCT) led to incremental advances in patient management in the 1990s. The clinical results for patients dramatically improved further in the 2000s with the introduction of immunomodulatory drugs and proteasome inhibitors. In the ‘modern’ era for MM treatment, transplant trials strongly support the use of upfront ASCT in the context of novel agents, and until proven otherwise, the old ASCT remains the standard of care for eligible patients. Nevertheless, some issues remain unresolved and this editorial aims to highlight the concerns to be addressed in the future.

Published
2015
Full Text
View/download PDF

21. Plerixafor: what we still have to learn

Author

Lanza, Francesco, Gardellini, Angelo, Laszlo, Daniele, and Martino, Massimo

Abstract

Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma. Current evidence suggests that the addition of plerixafor with chemotherapy plus G-CSF is safe and effective in the large majority of the patients with low blood CD34cell count after mobilization and/or poor yield after the first collection. Nevertheless, there are several questions strongly debated, and in this paper, we would like to identify areas of possible future use and development of the drug.

Published
2015
Full Text
View/download PDF

22. High-dose chemotherapy for germ cell tumors: do we have a model?

Author

Necchi, Andrea, Lanza, Francesco, Rosti, Giovanni, Martino, Massimo, Farè, Elena, and Pedrazzoli, Paolo

Abstract

Introduction:Since the late nineties, the intensification of chemotherapy doses with hematopoietic stem cell rescue held promise for patients with advanced and poor prognosis germ cell tumors (GCTs). High-dose chemotherapy (HDCT) has, nowadays, a recognized indication in the salvage setting of advanced GCTs and is steadily utilized worldwide.Areas covered:We evaluated the available data with the use of HDCT in these patients. In addition, we provided an original perspective on several issues as experts on behalf of the European Society for Blood and Marrow Transplantation and IGG, including peripheral blood stem cells mobilization and the use of HDCT in special subpopulations of GCT, with the aim to help clarify critical issues in the absence of available clear-cut information.Expert opinion:Despite HDCT being currently considered a therapeutic option in the salvage setting, critical questions regarding patient selection are still unanswered. Eligibility of patients with a chemoresistant disease, the use of available prognostic factors as well as tumor marker decline in clinical practice are pending issues. Moving forward, these are critical arguments in favor of further clinical research in the field of advanced GCTs.

Published
2015
Full Text
View/download PDF

23. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients

Author

Sandro Barni, Simona Secondino, Francesco Lanza, Giovanni Rosti, Daniele Generali, Massimo Martino, Paolo Pedrazzoli, Alberto Bottini, Luca Castagna, Roberto Maisano, Martino, Massimo, Bottini, Alberto, Rosti, Giovanni, Generali, Daniele, Secondino, Simona, Barni, Sandro, Maisano, Roberto, Lanza, Francesco, Castagna, Luca, and Pedrazzoli, Paolo

Subjects
Oncology, medicine.medical_treatment, High-risk breast cancer, Clinical Biochemistry, autologous transplantation, Antineoplastic Agent, high-risk breast cancer, High dose chemotherapy, stem cell mobilization and collection, Autologous hematopoietic progenitor cell transplantation, High-dose chemotherapy, Metastatic breast cancer, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Hematopoietic Stem Cell Transplantation, Humans, Randomized Controlled Trials as Topic, Transplantation, Autologous, Pharmacology, Drug Discovery3003 Pharmaceutical Science, Medicine (all), Drug Discovery, Transplantation, Autologou, metastatic breast cancer, Drug, Autologous, Breast Neoplasm, Human, medicine.medical_specialty, NO, Dose-Response Relationship, Breast cancer, Cell transplantation, Internal medicine, medicine, Overall survival, Chemotherapy, Transplantation, autologous hematopoietic progenitor cell transplantation, Antineoplastic Combined Chemotherapy Protocol, autologous hematopoietic progenitor cell transplantation, high-dose chemotherapy, high-risk breast cancer, metastatic breast cancer, stem cell mobilization and collection, autologous transplantation, business.industry, Animal, medicine.disease, Clinical trial, Hematopoietic progenitor, business, high-dose chemotherapy
Abstract

INTRODUCTION: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. AREAS COVERED: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. EXPERT OPINION: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results